Safety profile of ixekizumab, an anti–IL-17 monoclonal antibody, in chronic plaque psoriasis patients after at least 1 year of open label treatment - 16/03/14
Kenneth Gordon, MD, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States; Craig Leonardi, MD, St. Louis University School of Medicine, St. Louis, MO, United States; Daniel Braun, MD, Eli Lilly and Company, Indianapolis, IN, United States; Gregory Cameron, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Janelle Erickson, PhD, Eli Lilly and Company, Indianapolis, IN, United States; Mark Lebwohl, MD, The Mount Sinai School of Medicine, New York, NY, United States; Michael Heffernan, MD, Eli Lilly and Company, Indianapolis, IN, United States; Subhashis Banerjee, MD, Eli Lilly and Company, Indianapolis, IN, United States
Le texte complet de cet article est disponible en PDF.| Sponsored 100% by Eli Lilly and Company. |
Vol 70 - N° 5S1
P. AB184 - mai 2014 Retour au numéro
Article précédent
- Safety of ustekinumab from the placebo-controlled periods of psoriatic arthritis and psoriasis clinical developmental programs
- Secukinumab autoinjectors demonstrate patient satisfaction: An analysis of the Self-Injection Assessment Questionnaire (SIAQ) in the JUNCTURE Study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?